Q3 2024

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Novo Nordisk launches initiative to tackle childhood obesity
• EU regulators recommend Wegovy® label update to include heart failure benefits
• ESSENCE trial showcases semaglutide’s potential in MASH
• Performance highlights for Q3 2024
   

Q2 2024

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Application for semaglutide 1 mg label extension in the US
• Expansion of US manufacturing capacity
• Results from the FRONTIER 2 clinical trial
• Tackling CO2 emissions in a time of unprecedented growth
• Performance highlights for Q2 2024

Q1 2024

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Our priorities in CVD
• Cities for Better Health
• Novo Nordisk aims to boost production capacity through acquisitions
• Performance highlights for Q1 2024

Q3 2023

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Novo Nordisk adjusts its launch and distribution strategy amid global supply constraints
• Novo Nordisk to acquire clinical candidate for uncontrolled hypertension
• New partnership to supply human insulin to millions of people across the African continent
• Novo Nordisk halts once-weekly injectable semaglutide kidney outcomes trial based on positive interim analysis
• Novo Nordisk and UNICEF extend joint initiative to prevent global childhood obesity
   

Q2 2023

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• SELECT results show semaglutide 2.4 mg significantly reduces major adverse cardiovascular events
• Novo Nordisk continues investments to expand production capacity
• NEW FRONTIERS: Gene-editing partnership takes aim at hard-to-treat genetic disorders
• Novo Nordisk launches world’s first cross-industry solution for recycling injection pens
• Novo Nordisk to undertake 1:2 share split

Q1 2023

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Novo Nordisk raises sales and operating profit outlook for 2023
• A century of innovation, research and dedication
• Novo Nordisk announces lower insulin pricing in the US, effective from January 2024
• Oral semaglutide 25 mg and 50 mg show promise in phase 3 trial

Q3 2022

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes
• Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and other rare blood disorders
• Novo Nordisk partners with Microsoft to accelerate drug discovery and development using big data and artificial intelligence
• Saxenda^® obesity sales at an all-time high
   

Q2 2022

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Novo Nordisk invests in expansion of production capacity to meet growing patient demand
• A work of ‘smart’: Dialoq® launch brings digital connectivity to pre-filled insulin pens
• Driving change in diabetes, one pedal stroke at a time
• One step closer to bringing the world’s first once-weekly insulin treatment to patients

Q1 2022

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Our response to the war in Ukraine
• Taking obesity treatment to the next level
• Strengthening the pipeline in rare disease
• Harnessing the power of disruptive research technologies to develop next-generation treatments

Q3 2021

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Key milestone reached in fight to ensure no child dies from diabetes
• Production ramped up as initial demand for Wegovy in the US exceeds supply
• ASCVD: Taking aim at one of the world’s biggest killers
• Towards zero environmental impact: 15% reduction in CO2 emissions from suppliers

Q2 2021

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• New stem cell partnership targets chronic heart failure
• Ozempic® approved in China
• Novo Nordisk teams up with the University of Toronto to kickstart a new era in preventive public health
• Stepping up the game in obesity treatment: Wegovy^TM approved in the US

Q1 2021

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• R&D organisation evolves into two areas
• Oral semaglutide set to enter phase 3 development for Alzheimer’s disease
• Digital health: first smart pens launched in Sweden
• Rybelsus® launched in Japan – one of the world’s largest oral anti-diabetes markets

Q3 2020

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Phase 2 trial successfully completed with ziltivekimab
• Raised 2020 outlook on 8 October 2020
• Not if, but how: new strategy steps up our efforts to Defeat Diabetes
• 100% renewable power target for direct suppliers launched in 2020
• 100 years ‎young: why we’re investing in the future of insulin
   

Q2 2020

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Clinical results support Strategic Aspiration for obesity treatment
• Novo Nordisk acquires Corvidia Therapeutics and expands presence in cardiovascular disease
• Lose or reuse? How we are repurposing our insulin pens
• A deep dive into NASH and Novo Nordisk’s activities in tackling this disease
• Highlights from the first six months of 2020
   

Q1 2020

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• An unprecedented challenge: our response to COVID-19
• Rybelsus® approved in the EU
• Obesity through the lens: the truth from within
• Prevention or cure? When it comes to type 1 diabetes, we are working on both
• Highlights from the first three months of 2020

Q3 2019

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• A new era in diabetes care: Rybelsus® approved in the USA
• New affordability initiatives to be launched in the USA
• People and purpose: Monique Carter on driving culture change at Novo Nordisk
• Intensifying China’s fight against diabetes
• Highlights from the first six months of 2019

Q2 2019

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• A new mindset for environmental responsibility
• Obesity: The brain is the battleground
• Outcomes trials: Can semaglutide go even further in addressing patient needs?
• Maximising the growth potential
• Listen and lead: Ludovic Helfgott on returning biopharm to growth
• Highlights from the first six months of 2019

Q1 2019

SHARE Magazine UK |  SHARE Magazine DK

Index

• Message from the CEO
• Oral semaglutide filed in the US and EU
• The day I fired my doctor
• Safely in the Rainbow
• Shaped tablet key to oral delivery of insulin
• Novo Nordisk addresses affordable insulin
• Accelerating growth in Latin America
• Highlights from the first three months of 2019

Q3 2018

SHARE Magazine UK |  SHARE Magazine DK

Index

• Letter from the CEO, Lars Fruergaard Jørgensen
• Highlights from the first nine months of 2018
• Tresiba® revitalised with new ‘Hypos matter’ 
• Novo Nordisk research centre opens in oxford
• Connected insulin pens poised for launch

Q2 2018

SHARE Magazine UK | SHARE Magazine DK

Index

• Letter from the CEO, Lars Fruergaard Jørgensen
• Highlights from the first six months of 2018
• Oral semaglutide shows promising results
• Ozempic® heading for the European market
• Novo Nordisk focuses on treating obesity
• Red Cross and Novo Nordisk enters partnership

Q1 2018

SHARE Magazine UK

Index

• Letter from the CEO, Lars Fruergaard Jørgensen
• Highlights from the first three months of 2018
• Oral semaglutide shows promising results
• Ozempic® approved in the EU and Japan
• First phase 3a trial with oral semaglutide completed
• Updated Tresiba® label approved in the USA
• How Novo Nordisk’s products in Cuba

Q3 2017

SHARE Magazine UK | SHARE Magazine DK

Index

• Letter from the CEO, Lars Fruergaard Jørgensen
• Highlights from the first nine months of 2017
• Camilla Sylvest joins executive management
• SUSTAIN 7: Semaglutide compared to dulaglutide
• Victoza® CV label approved in the US and the EU
• Fiasp® a fast-acting insulin approved in the US
• Ambitious global goal: To prevent 100 million new cases of diabetes by 2045

Q2 2017

SHARE Magazine UK | SHARE Magazine DK

Index

• Letter from the CEO, Lars Fruergaard Jørgensen
• Highlights from the first six months of 2017
• Label update for Tresiba® submitted in the US
• A step closer towards a CV indication for Victoza®  
• Phase 2 obesity data for semaglutide
• New data on Xultophy® 
• Why Novo Nordisk is helping refugees

Q1 2017

SHARE Magazine UK | SHARE Magazine DK

Index

• Letter from the CEO, Lars Fruergaard Jørgensen
• Highlights from the first three months of 2017
• Doug Langa new head of North America Operations
• Fiasp® launched in Canada and EU markets
• New research centre in Oxford
• CHMP endorses Refixia® 
• World Diabetes Foundation 15 th anniversary